Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US9023356B2 · kind B2 · utility
0Cited by
195References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 14, 2008 |
| Grant date | May 5, 2015 |
| Priority date | — |
| Expiry date | Jun 14, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.